Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer

Background: Breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC) have increased recurrence risk. Molecular characterization, knowledge of NAC response, and simultaneous generation of patient-derived xenografts (PDXs) may accelerate drug development. However, the feasibil...

Descripción completa

Detalles Bibliográficos
Autores principales: Goetz, Matthew P., Kalari, Krishna R., Suman, Vera J., Moyer, Ann M., Yu, Jia, Visscher, Daniel W., Dockter, Travis J., Vedell, Peter T., Sinnwell, Jason P., Tang, Xiaojia, Thompson, Kevin J., McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Copland, John A, Northfelt, Donald W., Gray, Richard J., Hunt, Katie, Conners, Amy, Weinshilboum, Richard, Wang, Liewei, Boughey, Judy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408989/
https://www.ncbi.nlm.nih.gov/pubmed/28376176
http://dx.doi.org/10.1093/jnci/djw306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408989/
https://www.ncbi.nlm.nih.gov/pubmed/28376176
http://dx.doi.org/10.1093/jnci/djw306

Ejemplares similares